Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418154 | 0.79 | ESR2 (0.52) | ESR1ESR2 | |
| SCHEMBL5598119 | 0.76 | ESR2 (0.47) | ESR1ESR2 | |
| SCHEMBL3035977 | 0.69 | ESR2 (0.45) | ESR1ESR2 | |
| SCHEMBL1256728 | 0.68 | ESR1 (0.66) | ESR1ESR2 | |
| SCHEMBL15436438 | 0.67 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL400472 | 0.63 | ESR1 (0.35) | ESR1ESR2 | |
| SCHEMBL13885031 | 0.63 | HDAC4 (0.41) | ESR1ESR2 | |
| SCHEMBL15996377 | 0.63 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL12893318 | 0.63 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL397825 | 0.62 | ESR1 (0.40) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.